Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
ADC Therapeutics positioned the MedImmune transaction as validation of its PBD-warhead platform and a strategic capital injection covering two preclinical…
Industry-press coverage characterized the deal as MedImmune internalizing best-in-class PBD payload chemistry to compete with Seagen and Roche/Genentech in…
Spirogen was a UCL spin-out; UCLB framed the $200M upfront / $440M total transaction as a flagship UK academic-to-pharma technology-transfer outcome.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
MedImmune acquired Spirogen for $200M upfront + up to $240M milestones (total $440M); added PBD-warhead ADC platform plus ADC Therapeutics joint development of two preclinical programs.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Spirogen Limited (this deal) | 2013 | $440M | 30 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · AstraZeneca PLC deals · Oncology deals